The Global Market for Intravenous Immunoglobulin is Projected to Exceed US$11.1 Billion by 2020

Rising Number of Antibody Deficiency Indications Drive the Global Intravenous Immunoglobulin (IVIg) Market, According to a New Report by Global Industry Analysts, Inc.

GIA announces the release of a comprehensive global report on Intravenous Immunoglobulin (IVIg). The global market for Intravenous Immunoglobulin is projected to exceed US$11.1 billion by 2020, driven by the rise in prevalence of immunoglobulin deficiency.

The global Intravenous Immunoglobulin (IVIg) market is forecast to witness strong growth, supported by the growing awareness among patients over primary immunodeficiency disorders. Bio-based therapies are growing in popularity, the world over. IVIg represents the largest market for plasma-based therapeutic proteins, led by growing world population, and increase in average life expectancy. Approval of IVIg for new disease indications is expected to benefit market growth in the coming years. One of the key growth drivers for IVIg is the protein’s valuable use in the treatment of immune-mediated neurological disorders and primary immune deficiencies.

The biggest hope for Alzheimer’s therapeutics till 2013 was the potential FDA approval of IVIG for Alzheimer’s disease (AD), and off-label use of the same over the intervening period. IVIg has been tested since 2002 for its anti- Aβ antibody activity against AD, the neurodegenerative disease associated with cerebral accumulation of aggregated Aβ (amyloid beta). Advances in research revealed that Intravenous immunoglobulin (IVIg) fraction from normal human donor blood has the ability to provide passive immunotherapy for AD. In addition, chronic IVIg therapy was also found to hinder neuroinflammation associated with AD. Preclinical trial results were favorable and IGIg was found to increase brain metabolism and prevent cognitive decline. However, phase 1 and 2 trials were conducted in smaller patient groups, rendering uncertainty to the findings. While current results do not validate IVIg use for the treatment of AD, there is a need for additional studies to develop more effective immunoglobulin therapies for Alzheimer’s in the future. Despite opportunities for growth, the market is expected to confront challenges such as healthcare cost containment in developed countries, high cost of protein therapy, stringent government regulations including approval, and safety norms.

As stated by the new market research report on Intravenous Immunoglobulin (IVIg), the United States represents the largest market worldwide, followed by Europe. Asia-Pacific, led by China, is projected to witness strong growth. Key factors driving growth in developing countries include favorable demographics, rising awareness over the efficacy of plasma protein therapies, and increasing investments in healthcare infrastructure development. China, with its vast unmet medical needs offers robust opportunities for growth.

Major players in the market include Baxter International Inc., Beijing Tiantan Biological Products Co. Ltd., Bharat Serums and Vaccines Limited, Biotest AG, China Biologic Products Inc., CSL Limited, CSL Behring LLC., Grifols, S.A, Hualan Biological Engineering Inc., Kedrion S.p.A, LFB Group, Octapharma AG, OMRIX Biopharmaceuticals Ltd., Shanghai RAAS Blood Products Co. Ltd., and Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd, among others.

The research report titled  "Intravenous Immunoglobulin (IVIG): A Global Strategic Business Report" announced by Global Industry Analysts Inc., provides a comprehensive review of trends, growth drivers, restraints, market share, size and demand projections and forecasts. Major geographic regions covered are the US, Canada, Japan, Europe (France, Germany, Italy, UK, Spain, and Rest of Europe), Asia-Pacific (Australia, China and Rest of Asia-Pacific) and Rest of World. The report also offers coverage on mergers, acquisitions, product launches and other strategic industry activities of major global and regional players.